A: It is our proprietary method of analysing a company’s financial health at a granular level to ensure every component—from cash flow to governance—is optimized for an IPO or PE funding.
A: An SME IPO provides permanent capital, enhances brand visibility, and offers a clear valuation benchmark, whereas PE often involves giving up more control and having a fixed exit timeline.
A: Typically, the journey from Molecular Analysis to listing takes 6 to 9 months, depending on the company’s initial readiness and market conditions.
4. Q: Does Arpina help with funding before the IPO?
A: Yes. We often facilitate PE funding or VC rounds to bridge the gap and strengthen the balance sheet before the public debut.
Using Molecular Finance as our underlying theme, we treat each stage of the IPO journey not as a mere checklist, but as a process of "Financial Synthesis." We break down the complex structure of a company into its basic elements to ensure they bond perfectly for a successful public debut.
Copyright©2026 Arpina Optimus All Rights Reserved
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.